Balding Philip R, Porro Cristina S, McLean Kirsty J, Sutcliffe Michael J, Maréchal Jean-Didier, Munro Andrew W, de Visser Sam P
Manchester Interdisciplinary Biocentre, University of Manchester, 131 Princess Street, Manchester M1 7DN, United Kingdom.
J Phys Chem A. 2008 Dec 18;112(50):12911-8. doi: 10.1021/jp802087w.
To examine how azole inhibitors interact with the heme active site of the cytochrome P450 enzymes, we have performed a series of density functional theory studies on azole binding. These are the first density functional studies on azole interactions with a heme center and give fundamental insight into how azoles inhibit the catalytic function of P450 enzymes. Since azoles come in many varieties, we tested three typical azole motifs representing a broad range of azole and azole-type inhibitors: methylimidazolate, methyltriazolate, and pyridine. These structural motifs represent typical azoles, such as econazole, fluconazole, and metyrapone. The calculations show that azole binding is a stepwise mechanism whereby first the water molecule from the resting state of P450 is released from the sixth binding site of the heme to create a pentacoordinated active site followed by coordination of the azole nitrogen to the heme iron. This process leads to the breaking of a hydrogen bond between the resting state water molecule and the approaching inhibitor molecule. Although, formally, the water molecule is released in the first step of the reaction mechanism and a pentacoordinated heme is created, this does not lead to an observed spin state crossing. Thus, we show that release of a water molecule from the resting state of P450 enzymes to create a pentacoordinated heme will lead to a doublet to quartet spin state crossing at an Fe-OH(2) distance of approximately 3.0 A, while the azole substitution process takes place at shorter distances. Azoles bind heme with significantly stronger binding energies than a water molecule, so that these inhibitors block the catalytic cycle of the enzyme and prevent oxygen binding and the catalysis of substrate oxidation. Perturbations within the active site (e.g., a polarized environment) have little effect on the relative energies of azole binding. Studies with an extra hydrogen-bonded ethanol molecule in the model, mimicking the active site of the CYP121 P450, show that the resting state and azole binding structures are close in energy, which may lead to chemical equilibrium between the two structures, as indeed observed with recent protein structural studies that have demonstrated two distinct azole binding mechanisms to P450 heme.
为研究唑类抑制剂如何与细胞色素P450酶的血红素活性位点相互作用,我们对唑类结合进行了一系列密度泛函理论研究。这些是关于唑类与血红素中心相互作用的首批密度泛函研究,为唑类如何抑制P450酶的催化功能提供了基本见解。由于唑类有多种类型,我们测试了三种典型的唑类基序,它们代表了广泛的唑类和唑类型抑制剂:甲基咪唑酸盐、甲基三唑酸盐和吡啶。这些结构基序代表典型的唑类,如益康唑、氟康唑和甲吡酮。计算结果表明,唑类结合是一个逐步的机制,首先P450静止状态下的水分子从血红素的第六个结合位点释放,形成一个五配位活性位点,随后唑类氮与血红素铁配位。这个过程导致静止状态水分子与接近的抑制剂分子之间的氢键断裂。虽然从形式上看,水分子在反应机制的第一步被释放并形成一个五配位血红素,但这并未导致观察到的自旋态交叉。因此,我们表明,P450酶静止状态下释放一个水分子以形成五配位血红素,将在铁-羟基(2)距离约为3.0埃时导致二重态到四重态的自旋态交叉,而唑类取代过程发生在更短的距离。唑类与血红素结合的结合能比水分子强得多,因此这些抑制剂会阻断酶的催化循环,防止氧气结合和底物氧化催化。活性位点内的扰动(例如极化环境)对唑类结合的相对能量影响很小。在模型中添加一个额外的氢键乙醇分子进行的研究,模拟了CYP121 P450的活性位点,结果表明静止状态和唑类结合结构在能量上接近,这可能导致两种结构之间的化学平衡,正如最近的蛋白质结构研究中所观察到的,该研究证明了唑类与P450血红素存在两种不同的结合机制。